24
Participants
Start Date
May 11, 2016
Primary Completion Date
August 6, 2019
Study Completion Date
September 1, 2022
MEDI4736
MEDI4736 is formulated at 50 mg/mL in 26 mM histidine/histidine-HCl, 275 mM trehalose dihydrate, 0.02% (w/v) polysorbate 80, pH 6.0.
Tremelimumab
Tremelimumab Drug Product is formulated at a nominal concentration of 20 mg/mL in 20 mM histidine/histidine hydrochloride, 222 mM trehalose dihydrate, 0.02% (weight/volume \[w/v\]) polysorbate 80, 0.27 mM disodium edetate dihydrate (EDTA), pH 5.5.
no other name
Neither MEDI4736 nor Tremelimumab will be used.
Baylor St Lukes, Houston
Baylor College of Medicine
OTHER